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http://dx.doi.org/10.1016/j.immuni.2012.05.004Most immunology textbooks still promote
the age-old idea that the sole function of
mast cells is to mediate immunoglobulin
E (IgE)-dependent responses in allergy
and parasitic worm infections. But mast
cells are extremely versatile cells and
can be stimulated by numerous IgE-inde-
pendent agonists, including pathogen-
associated molecular pattern molecules
(PAMPs), cytokines, hormones, and
neuropeptides as well as through cell-
cell interactions. Depending on the activa-
tion mode, mast cells exhibit varied and
‘‘tunable’’ responses, releasing unique
arrays of preformed and newly synthe-
sized pro- and/or anti-inflammatory medi-
ators (RaoandBrown, 2008). This concept
of a more multifunctional mast cell has
been reinforced by a plethora of data doc-
umenting the contributions of these cells
to protective immunity in viral and bacte-
rial infections, in maintaining homeostasis
and immunologic tolerance, and in exac-
erbating pathologic inflammation associ-
ated with cancer, heart disease, and
autoimmunity (Rao and Brown, 2008).
Collectively, these studies indicate that
IgE-mediated responses may constitute
only a small fraction of mast cells’ role in
immunity.
However, data presented in a recent
Immunity paper challenge this concept
of a more versatile mast cell (Feyerabend
et al., 2011). With a newly generated mast
cell-deficient mouse strain, the authors
fail to observe a role for mast cells in
models of rheumatoid arthritis (RA) and
multiple sclerosis (MS), diseases previ-
ously demonstrated to be mast cell
dependent. They propose that the classic
model systems used to assign mast cell
activities in vivo have led to an overesti-
mation of their roles in health and disease,
an idea supported by Katz and Austen
(2011) in their accompanying preview.
Yet in making this argument, the authors
ignore overwhelming evidence support-
ing the diverse functions of mast cells.
Furthermore, their studies of experimental
autoimmune encephalomyelitis (EAE), therodent model of MS, use an experimental
approach that probably obscures mast
cell contributions to this T cell-dependent
disease.
Until recently, in vivo studies of mast
cells relied primarily on the use of mice
carrying naturally occurring mutations
at the White spotting locus (W), which
includes Kit encoding the stem cell factor
receptor c-kit. Mice bearing certain Kit
mutations that compromise c-kit signaling
function, W/Wv and Wsh/Wsh, exhibit
profound defects in mast cell develop-
ment (reviewed in Rao and Brown,
2008). By comparing the phenotype of
Kit mutant mice and their wild-type litter-
mates in disease models, it is possible to
determine whether mast cells are likely
contributors. The reversal of an altered
phenotype in Kitmutant mice upon selec-
tive mast cell reconstitution is considered
to be a confirmation of their role. However,
there are otherKit-related abnormalities in
these mice that limit their use, including
reduced fertility, anemia, neutropenia, or
neutrophilia. In addition, it is argued that
residual precursor cells can contaminate
the bone marrow-derived mast cells
used in reconstitution leading to the resto-
ration of other cell lineages affected
by Kit mutations. This can compromise
the ability to distinguish between defects
that are influenced by the loss of mast
cells and those resulting from other c-kit-
regulated processes. Thus, there has
been a great need for improved versions
of mast cell-deficient mice.
In just the last year several unique
mouse strains have been reported,
providing hope that the contributions of
these ‘‘enigmatic’’ cells can finally be veri-
fied (Dudeck et al., 2011; Feyerabend
et al., 2011; Lilla et al., 2011; Otsuka
et al., 2011). Included is the ‘‘Cre-master’’
(Cpa3Cre/+)mouse,whichcontainsa trans-
gene encoding Cre-recombinase under
the control of the carboxypeptidase 3
(Cpa3) promoter inserted within the first
exon of Cpa3 (Feyerabend et al., 2011).
High expression of Cre-recombinase inImmunityCPA3-expressing mast cell precursors is
toxic and causes genomic instability and
the ultimate demise of this lineage at an
early stage in development. With the
exception of reduced numbers of baso-
phils, cells that share a common CPA3-
expressingprecursor, there is noevidence
that other lineages are affected.
The ability to elicit mast cell-depen-
dent responses in two IgE-mediated
disease models is profoundly impaired
in Cpa3Cre/+ mice. These mice are refrac-
tory to the induction of anaphylaxis, and
in N. brasiliensis infection, the normal
protective expansion of mast cells in
the intestines fails to occur. These results
presumably validate the use of Cpa3Cre/+
mice for defining mast cell contributions
to immunity. Yet no diminution of EAE
or RA disease severity is observed in
Cpa3Cre/+ mice compared to their wild-
type littermates leading to the conclusion
that mast cells are dispensable. Of
interest, although KitW/W-v mice fail to
develop serum-transferred arthritis as
previously reported (Lee et al., 2002),
the severity of EAE is comparable to
wild-type controls in their hands. The
authors suggest that the loss of RA
disease susceptibility in Kit mutant mice
must be attributed to other c-kit-related
defects. They further postulate that biased
scoring and differences in colony micro-
biota account for the laboratory-specific
differences observed in EAE severity.
We contend that there are other explana-
tions for the disparate EAE results that
are based on the fact that IgE-mediated
responses and to autoimmune disease
are fundamentally different.
Mast cells are the major effector cells in
responses to helminth infection or those
leading to allergy and anaphylaxis and
because the relevant mast cell popula-
tions are absent in both Cpa3Cre/+ and
Kit mutant mice, neither strain can
generate a normal response in these
models. In contrast, self-reactive T cells
and/or antibody-producing B cells are
the major effectors in the development36, June 29, 2012 ª2012 Elsevier Inc. 891
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Lettersof autoimmunity and act by directing
a pathologic immune response to the
target tissue, in part through recruitment
of other accessory inflammatory cells. In
such settings mast cells, by definition,
can play only a modifying role at best.
And herein lies the problem. Mast cells
amplify EAE disease severity but are not
absolutely essential for its development.
Because the immune system is redun-
dant, the precise conditions used to
induce EAE (e.g., age of mice, peptide
dose, adjuvant concentration, route of
immunization) are critical for accurately
revealing the influence of accessory cells
such as mast cells. In their experiments,
Feyerabend et al. (2011) probably used
an EAE-induction protocol that promotes
a strong initial T cell response, one that
does not recapitulate the gradual evolu-
tion of this response in MS and results in
such overwhelming inflammation that it
masks the mast cell contribution. This
interpretation is corroborated by the high
morbidity of a substantial proportion of
mice in these experiments (Feyerabend
et al., 2011, Figure S6C) as well as data
from our own laboratory (data not shown)
and that reported by Piconese et al.
(2011), which demonstrate that mast cell
dependence in EAE varies with the
immunization conditions used. The inves-
tigators also fail to confirm that mast
cell populations relevant in EAE, particu-
larly in the meninges, are depleted in
Cpa3Cre/+ mice. Taken together, these
data undermine the argument that mast
cells are irrelevant in this model. Paradox-
ically, the investigators used mast cell
reconstitution, which if properly per-
formed does not repair other c-kit-related
abnormalities, to validate the role of
mast cells in anaphylactic responses of
Cpa3Cre/+ mice, and yet they dismiss the
previous use of this type of confirmatory
experiment in Kit mutant mice.892 Immunity 36, June 29, 2012 ª2012 ElsevThe idea that mast cells contribute to
EAE orMS has been somewhat controver-
sial formanyyears.But evidence fromboth
human and mouse studies supports the
ideamastcells exacerbatedisease (Walker
et al., 2012). In animal studies, substantially
attenuated disease is observed in Kit
mutant mice in both the chronic C57BL/6
MOG35-55-induced and the relapsing-
remitting SJL PLP139-151-induced models
of MS. These results are not due to
‘‘biased’’ and subjective clinical scoring
as asserted because at least in the
relapsing-remitting model, both SJL+/+
and SJLW/W-v mice are white, which allows
blinded scoring of disease severity (Sayed
et al., 2011). A number of objectively
assessed parameters also lend credence
to the conclusion that mast cells are
involved. These include evidence of mast
cell activation in humans and mice in early
disease as well as diminished disease-
associated immune cell infiltration to the
CNS and blood brain barrier permeability
in W/Wv mice, phenotypes that are
reversed by BMMC reconstitution (Walker
et al., 2012).
In their preview, Katz and Austen (2011)
assert that the most, if not only, relevant
mode of mast cell activation is through
the high-affinity IgE receptor FcεRI. They
propose that it is not mast cells, but
other myeloid-lineage cells, that influence
autoimmune responses (see Katz and
Austen, 2011, Figure 1). If mast cell influ-
ences are limited to those that require
IgE-receptor activation, how can the pres-
enceandwell-documented functionality of
the myriad of non-Ig activation receptors
expressed on mast cells be explained?
The strong evidence of mast cell interac-
tions with T cells, dendritic cells, and
neutrophils as well as CNS-resident astro-
cytes is also ignored when considering
potential mast cell effects on autoimmune
diseases (Walker et al., 2012).ier Inc.There is no doubt that the development
of Cpa3Cre/+ mice and related mast cell-
deficient mouse lines is an important
advance inmast cell biology andwill allow
the definitive delineation of mast cells’
contributions in vivo. Critical to this effort,
however, will be the proper application of
relevant andwell-validated approaches to
assess the variety of questions in this
field. There is much work to be done
before we begin to disassemble the large
body of evidence that mast cells are
indeed ‘‘master’’ cells of immunity.REFERENCES
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